lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed and are posted here as part of a 12-month trial. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

A Modified Phase 1 Clinical Trial of Abivertinib (Ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer

29 Pages Posted: 6 Dec 2018

See all articles by Qing Zhou

Qing Zhou

Government of the People's Republic of China - 307th Hospital

Xiao-Qing Liu

Government of the People's Republic of China - 307th Hospital

Pei Hu

Chinese Academy of Medical Sciences

Jian-Ying Zhou

Zhejiang University

Li Zhang

Chinese Academy of Medical Sciences

Tong-Tong An

Central South University

Lin Wu

Peking University - Cancer Hospital and Institute

Ying Cheng

Jilin Province Cancer Hospital

Ji Jiang

Chinese Academy of Medical Sciences

Zhi-Hong Chen

Guangdong Academy of Medical Sciences

Bin Gan

Guangdong Academy of Medical Sciences

Wan-Hong Xu

ACEA Pharmaceutical Research

Feng R Luo

ACEA Therapeutics Inc.

Li Xu

ACEA Therapeutics Inc.

Xiao Xu

ACEA Therapeutics Inc.

Yi-Long Wu

Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangdong Lung Cancer Institute, Department of Pulmonary Oncology

More...

Abstract

Background: Abivertinib is a novel, third-generation EGFR tyrosine kinase inhibitor. We investigated the safety and efficacy of abivertinib in Chinese patients with EGFR T790Mpositive non-small cell lung cancer (NSCLC) and determined the recommended Phase II dose (RP2D).

Methods: This open-label, single-arm, dose-escalation study enrolled patients (18–75 years) with disease progression on prior EGFR TKIs from 8 centers in China. Patients received abivertinib 50–350 mg BID in sequential cohorts using a dose escalation/expansion protocol which determined dose-limiting toxicities (DLTs) in Cycle 1 and evaluated the clinical activity of abivertinib. RP2D (primary endpoint) was based on DLTs along with available safety, efficacy and pharmacokinetic data. Secondary endpoints included overall response rate (ORR), progression-free survival (PFS), and safety. This study is registered with ClinicalTrials.gov (NCT02330367).

Findings: Between January 2015 and March 2018, 140 patients received abivertinib for a median (range) of 21·7 (1·3–148) weeks. Median relative dose intensity was 99%. Maximum tolerated dose was not reached with only 3 DLTs observed across all doses. RP2D was 300 mg BID based on a median (range) PFS of 6·9 (3·0, 9·0) months, ORR of 40% and broadly comparable safety profile to the 50–300 mg BID doses. Grade 3/4 treatment-related adverse events were more frequent with abivertinib 350 mg BID (4/6 patients, 67%) versus 300 mg BID (12/45, 27%) and lower doses. Minimal accumulation of abivertinib was observed at steady state across the studied doses and exposure rose proportionally with increasing dose.

Interpretation: Abivertinib 150–300 mg BID represented the efficacious range while 350 mg BID dose had the least favorable safety profile, suggesting 300 mg BID as the RP2D. This novel study design which considered efficacy, pharmacokinetics, and safety beyond Cycle 1 in addition to DLTs may facilitate RP2D determination for drugs with favorable toxicity profiles.

Clinical Trial Number: This study is registered with ClinicalTrials.gov (NCT02330367).

Funding Statement: This study was funded by ACEA Therapeutics Inc.

Declaration of Interests: W-HX is an employee of ACEA Pharmaceutical Research, Hangzhou, China. FL, LX and XX are employees of ACEA Therapeutics Inc. QZ declares speaker fees from AstraZeneca and Roche. LW declares speaker fees from AstraZeneca, Eli Lilly, Pfizer, Roche, and Sanofi. YLW declares speaker fees from AstraZeneca, Eli Lilly, Pfizer, Roche, and Sanofi. X-QL, PH, J-YZ, LZ, T-TA, YC, JJ, Z-HC, and BG declare no competing interests.

Ethics Approval Statement: The study was conducted according to the ethical principles established in the Declaration of Helsinki and was consistent with the Chinese Good Clinical Practice Guidelines. The study protocol was approved by the institutional review board or independent ethics committee at each study center.

Keywords: abivertinib; AC0010; EGFR; NSCLC; T790M; Phase 1

Suggested Citation

Zhou, Qing and Liu, Xiao-Qing and Hu, Pei and Zhou, Jian-Ying and Zhang, Li and An, Tong-Tong and Wu, Lin and Cheng, Ying and Jiang, Ji and Chen, Zhi-Hong and Gan, Bin and Xu, Wan-Hong and Luo, Feng R and Xu, Li and Xu, Xiao and Wu, Yi-Long, A Modified Phase 1 Clinical Trial of Abivertinib (Ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer (November 28, 2018). Available at SSRN: https://ssrn.com/abstract=3294124

Qing Zhou

Government of the People's Republic of China - 307th Hospital

China

Xiao-Qing Liu

Government of the People's Republic of China - 307th Hospital

China

Pei Hu

Chinese Academy of Medical Sciences

NO. 9, Dongdan Santiao
Beijing, Dongcheng District
China

Jian-Ying Zhou

Zhejiang University

38 Zheda Road
Hangzhou, Zhejiang 310058
China

Li Zhang

Chinese Academy of Medical Sciences

NO. 9, Dongdan Santiao
Beijing, Dongcheng District
China

Tong-Tong An

Central South University

Changsha, Hunan 410083
China

Lin Wu

Peking University - Cancer Hospital and Institute

No. 38 Xueyuan Road
Haidian District
Beijing, Beijing 100871
China

Ying Cheng

Jilin Province Cancer Hospital

Changchun
China

Ji Jiang

Chinese Academy of Medical Sciences

NO. 9, Dongdan Santiao
Beijing, Dongcheng District
China

Zhi-Hong Chen

Guangdong Academy of Medical Sciences

Daxuecheng Outer Ring E Rd,
Panyu Qu
Guangzhou Shi, Guangdong Sheng
China

Bin Gan

Guangdong Academy of Medical Sciences

Daxuecheng Outer Ring E Rd,
Panyu Qu
Guangzhou Shi, Guangdong Sheng
China

Wan-Hong Xu

ACEA Pharmaceutical Research

Hangzhou
China

Feng R Luo

ACEA Therapeutics Inc.

San Diego, CA
United States

Li Xu

ACEA Therapeutics Inc.

San Diego, CA
United States

Xiao Xu

ACEA Therapeutics Inc.

San Diego, CA
United States

Yi-Long Wu (Contact Author)

Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangdong Lung Cancer Institute, Department of Pulmonary Oncology ( email )

China

Click here to go to TheLancet.com

Go to TheLancet.com

Paper statistics

Abstract Views
38
Downloads
6